Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches

HIV infection induces systemic inflammation and microbial dysbiosis, contributing to long-term health complications despite effective antiretroviral therapy (ART). One of the major concerns is the persistence of gut barrier disruption, which leads to microbial translocation and immune activation. Th...

Descripción completa

Detalles Bibliográficos
Autor: Talavera Rodríguez, Alba María
Tipo de recurso: tesis doctoral
Fecha de publicación:2025
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/131021
Acceso en línea:https://hdl.handle.net/20.500.14352/131021
Access Level:acceso abierto
Palabra clave:616.98:578.828 VIH(043.2)
Infecciones por virus del SIDA
HIV infections
Microbiología médica
2420 Virología
id ES_bb600aee2c6b7b3bf17a75138f86c58b
oai_identifier_str oai:docta.ucm.es:20.500.14352/131021
network_acronym_str ES
network_name_str España
repository_id_str
spelling Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approachesMicrobioma intestinal y VIH : relación con la inflamación crónica y el hígado graso mediante enfoques metagenómicos =Talavera Rodríguez, Alba María616.98:578.828 VIH(043.2)Infecciones por virus del SIDAHIV infectionsMicrobiología médica2420 VirologíaHIV infection induces systemic inflammation and microbial dysbiosis, contributing to long-term health complications despite effective antiretroviral therapy (ART). One of the major concerns is the persistence of gut barrier disruption, which leads to microbial translocation and immune activation. The gut microbiome plays a crucial role in immune regulation, and its alterations in people with HIV (PWH) have been linked to disease progression, immune dysfunction, and comorbidities like metabolic dysfunction-associated steatotic liver disease (MASLD).Bacterial translocation is a key factor in chronic inflammation, making microbiota-targeted therapies a promising area of research. Strategies such as probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT) have been explored to mitigate inflammation and restore microbial balance. Among these, FMT has shown potential as a therapeutic intervention. In this work, we found that repeated FMT in PWH on ART was safe and not associated with serious adverse effects. Additionally, it reduced intestinal fatty acid-binding protein (IFABP) levels, a biomarker of intestinal injury predictive of mortality in treated PWH, without affecting T-cell markers...Universidad Complutense de MadridSerrano Villar, SergioFernández Lanza, ValUniversidad Complutense de Madrid20252025-01-2620252025-01-26doctoral thesishttp://purl.org/coar/resource_type/c_db06info:eu-repo/semantics/doctoralThesisapplication/pdfhttps://hdl.handle.net/20.500.14352/131021reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1310212026-06-02T12:44:21Z
dc.title.none.fl_str_mv Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
Microbioma intestinal y VIH : relación con la inflamación crónica y el hígado graso mediante enfoques metagenómicos =
title Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
spellingShingle Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
Talavera Rodríguez, Alba María
616.98:578.828 VIH(043.2)
Infecciones por virus del SIDA
HIV infections
Microbiología médica
2420 Virología
title_short Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
title_full Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
title_fullStr Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
title_full_unstemmed Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
title_sort Gut microbiome and HIV : relationship with chronic inflammation and fatty liver through metagenomic approaches
dc.creator.none.fl_str_mv Talavera Rodríguez, Alba María
author Talavera Rodríguez, Alba María
author_facet Talavera Rodríguez, Alba María
author_role author
dc.contributor.none.fl_str_mv Serrano Villar, Sergio
Fernández Lanza, Val
Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 616.98:578.828 VIH(043.2)
Infecciones por virus del SIDA
HIV infections
Microbiología médica
2420 Virología
topic 616.98:578.828 VIH(043.2)
Infecciones por virus del SIDA
HIV infections
Microbiología médica
2420 Virología
description HIV infection induces systemic inflammation and microbial dysbiosis, contributing to long-term health complications despite effective antiretroviral therapy (ART). One of the major concerns is the persistence of gut barrier disruption, which leads to microbial translocation and immune activation. The gut microbiome plays a crucial role in immune regulation, and its alterations in people with HIV (PWH) have been linked to disease progression, immune dysfunction, and comorbidities like metabolic dysfunction-associated steatotic liver disease (MASLD).Bacterial translocation is a key factor in chronic inflammation, making microbiota-targeted therapies a promising area of research. Strategies such as probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT) have been explored to mitigate inflammation and restore microbial balance. Among these, FMT has shown potential as a therapeutic intervention. In this work, we found that repeated FMT in PWH on ART was safe and not associated with serious adverse effects. Additionally, it reduced intestinal fatty acid-binding protein (IFABP) levels, a biomarker of intestinal injury predictive of mortality in treated PWH, without affecting T-cell markers...
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-01-26
2025
2025-01-26
dc.type.none.fl_str_mv doctoral thesis
http://purl.org/coar/resource_type/c_db06
dc.type.openaire.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/131021
url https://hdl.handle.net/20.500.14352/131021
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Complutense de Madrid
publisher.none.fl_str_mv Universidad Complutense de Madrid
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418020222271488
score 15.812429

Similares en LA Referencia